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Abstract:  The MST/Salvador-Warts-Hippo and mTOR/Akt/PI3K growth signaling 
pathways have been established as important modulators of cell growth, proliferation and 
cell survival in controlling organ size in Drosophila and mammals. Here, we sought to 
determine the role of the MST family of kinases, some of which are components of the 
Hippo pathway, and their closely related Sterile 20-like kinases (STK) as candidates for 
mediating cross-talk between the Hippo and mTOR pathways. Expression analysis in the 
HepG2 and MCF7 cell lines demonstrated common expression of MST1/2/4, MAP4K3/4/5, 
STK 24 (MST3), STK25, STK393DN6/.6WUDGĮȕDQG7$2. All components of the 
Hippo signaling pathway are present in both cell lines except for YAP1 in MCF7 cells. 
mTOR inhibition via rapamycin decreases TAZ levels in HepG2 but not MCF7 cells and 
increases TEAD1 levels in MCF7 but not HepG2 cells, suggesting a selective role of the 
mTOR pathway in regulating these Hippo targets in a cell type-specific manner. 
Furthermore, the cellular localization of TAZ changes in response to mTORC1/2 inhibitors 
and Akt inhibition. These findings demonstrate the mTOR-dependent regulation of Hippo 
signaling at the level of the transcriptional regulators TAZ and TEAD1 and highlight the 
potential role for mTOR inhibitors in regulating Hippo-signaling dependent tumors.  
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1. Introduction 
The development of cancer and tumorigenesis in eukaryotic cells occurs as a result of uncontrolled 
cell growth and division and ultimately leads to abnormal tissue growth. The Salvador-Warts-Hippo 
(SWH) tumor suppressor and the mammalian target of rapamycin (mTOR) pathways have been 
implicated as key regulators of both cell proliferation and apoptosis [1]. The SWH pathway, first 
described in Drosophila, is an evolutionarily conserved molecular mechanism that in mammals 
consists of a cassette of core kinases, including MST1/2 (Hippo homologue), Lats1/2 (Warts 
homologue), Mob (Mats homologue), as well as an adaptor protein, Sav1 (Salvador homologue) [2]. 
Earlier studies have shown that the downstream effectors of this kinase cassette include the 
transcription coactivators YAP1/2 and TAZ (Yorkie homologues), which work in conjunction with the 
TEAD transcription factor (Scalloped homologue) to promote cell proliferation and survival [3]. Lats 
acts in association with Mob to negatively regulate these two nuclear proteins by phosphorylation of 
YAP and TAZ, a sign of active Hippo signaling [4]. In the absence of phosphorylation, YAP and TAZ 
translocate to the nucleus, where they activate TEAD1 targets [5]. Upstream of the core kinase group, 
several kinases have also been found to be implicated in the SWH signaling pathway [6]. The 
mechanisms by which most of these upstream elements are regulated, however, have yet to be 
elucidated [7,8].  
Hippo/MST belongs to the family of kinases that share homology with Sterile 20p (Ste20p), a 
serine/threonine mitogen-activated protein kinase (MAPK) which was first discovered in yeast [9]. Its 
mammalian homologues, MST1 and MST2, are kinases that comprise a subset of the family of about 
28 Ste20-like protein kinases that have been discovered in mammals [10]. These kinases function as 
messengers for both intracellular and extracellular signals that include signal transduction among 
various other functions [11]. The Ste20p family consists of two structurally distinct subfamilies, the  
p21-activated kinase (PAK) family and the germinal center kinase (GCK) family. Ste-20 like kinases 
have been established to be important regulators of the MAP kinase cascades that respond to 
extracellular signals to regulate gene expression. One of the MAPK activators, the Ras-ERK pathway, 
has been found to regulate the mTOR pathway, which uses extracellular signals such as nutrient 
availability to control cell fate in cell survival, growth and metabolism [12]. This raises the interesting 
possibility that Ste20-like kinases may regulate or mediate the cross-talk between different growth 
signaling pathways, in particular MST1 and MST2, which have been identified as major components 
of the SWH pathway [13]. In this study we examine the expression of SWH pathway components as 
well as several of the Ste20-like kinases in the hepatocarcinoma HepG2 and breast cancer MCF7 cell 
lines. We identify a role for mTOR activity in regulating TAZ and TEAD1 levels as well as the 
intracellular localization of TAZ, linking the growth-promoting effects of the SWH and mTORC1 
pathways.  
2. Results and Discussion 
2.1. Hippo Pathway Components and STK Kinases Are Expressed in HepG2 and MCF7 Cell Lines 
In order to determine the regulation of the SWH pathway in the HepG2 cell line, we first tested for 
expression of transcripts for the core components of the pathway and Ste20-like kinases. We identified Cells 2012, 1  888 
 
 
expression of all the components involved in Hippo signaling (Mob1, NF2, MST1/2, Lats2) and their 
downstream effectors (TEAD1, TAZ, YAP1) in HepG2 cells. We also found that several Ste20-like 
kinases are expressed in HepG2 cells. These kinases include: Pak1, SLK, TAO2, MAP4K3, MAP4K4, 
0$3. 6WUDGĮȕ 067 STK24 (MST3), STK25, STK39 and Scrib (Figure 1A). Other genes 
tested for but not expressed include: Fat2, YSK4 and TAO3. Pak1, TAO2, MAP4K3, MAP4K5, 
STK24 (MST3), STK25, and Scrib are expressed at low levels.  
Figure 1. Expression of Hippo pathway components and Ste20-like kinases in HepG2 and 
MCF7 cell lines. (A) Transcript expression levels of Hippo pathway components (left) and 
Ste20-like kinases (right) do not change in response to rapamycin treatment in HepG2 
cells. Mob1, TAO2, Map4K5 and Scrib are expressed at very low levels. (B) Expression 
levels of Hippo pathway components and Ste20-like kinases transcripts do not change in 
response to rapamycin treatment in MCF7 cells. Pak1, TAO2, Map4K3, Map4K46WUDGĮ
and STK24 are expressed at low levels. YAP1 is not expressed. Note: Mob1, Map4K5, 
STK25 and Scrib are expressed at higher levels in MCF7 cells than in HepG2 cells, while 
0DS.DQG6WUDGĮDUHH[SUHVVHGDWORZHUOHYHOVLQ0&)FHOOVWKDQLQ+HS*FHOOV For 
both cell lines, GAPDH and the ribosomal protein rpS6 are included as housekeeping gene 
controls.  
 
(A)         ( B )  
Similar findings were observed for the MCF7 cell line (Figure 1B). We identified the expression of 
Hippo signaling components (Mob1, NF2, MST1/2, Lats2) and their targets TEAD1 and TAZ in these 
cells. Importantly, we noted the absence of YAP transcripts. This result was further confirmed through 
immunocytochemical analysis (Figure S1). Ste20-like kinases expressed include: Pak1, SLK, TAO2, 
MAP4K3, MAP4K40$3.6WUDGĮȕSTK24 (MST3), MST4, STK25, STK39, and Scrib. Other 
genes tested for but not expressed include: Fat2, YSK4 and TAO3. Mob1, MAP4K5, STK25 and Scrib 
DUHH[SUHVVHGDWKLJKHUOHYHOVLQ0&)FHOOVWKDQLQ+HS*FHOOVZKLOH0$3.DQG6WUDGĮ are Cells 2012, 1  889 
 
 
expressed at lower levels in MCF7 cells than in HepG2 cells. 2.2. Inhibition of mTOR Signaling Does 
Not Affect Transcription of Hippo and Ste20-like Kinases in HepG2 and MCF7 Cell Lines 
Signaling through mTOR occurs through two different complexes: mTORC1 and mTORC2 [14]. 
Rapamycin inhibits mTORC1 by inhibiting the interaction of Raptor with mTOR [15,16]. To study the 
effect of mTOR on Hippo signaling, we blocked mTOR activity by adding rapamycin to HepG2 cells 
and re-examined expression of Hippo components and Ste20-like kinases. We observed no changes in 
expression of pathway components and Ste20-like kinases when cells were treated with rapamycin 
(Figure 1A). Similar studies in MCF7 cells confirmed the same results (Figure 1B). Taken altogether, 
these results demonstrate that mTOR signaling does not regulate Hippo or Ste20-like kinase levels at 
the transcriptional level. 
2.2. Rapamycin Alters TEAD1 Protein Expression in MCF7 Cells 
We determined the intracellular localization and expression levels of the Hippo target YAP, for 
both its phosphorylated and unphosphorylated forms, in HepG2 cells, via immunocytochemistry in low 
and high cell density conditions (Figure S2). We observed that YAP and P-YAP proteins are mainly 
cytosolic and their expression levels or intracellular localization do not appear to be affected by cell 
density. Upon treatment with rapamycin, we observed that YAP and P-YAP remained cytosolic with 
drug treatment and that the expression levels of YAP and P-YAP did not change in response to cell 
density (Figure S2).  
In contrast, the transcription factor TEAD1, a binding partner for YAP and target of the Hippo 
pathway, is mainly nuclear at low cell density conditions, but less nuclear at high density in HepG2 
cells (Figure 2). While no appreciable change in TEAD1 expression was found upon treatment with 
drug in both high and low cell density conditions, rapamycin enhances the nuclear localization of 
TEAD1 in both cell density conditions (Figure 2). However, TEAD1 is mainly cytosolic in MCF7 
cells and its expression levels increase upon treatment with rapamycin without affecting intracellular 
localization (Figure 3). We further confirmed these findings by using an inhibitor of both mTORC1 
and mTORC2, OSI-027 [17] (Figure 4). A similar increase in TEAD1 levels was observed upon Akt 
inhibition, but not with upregulation of Akt activity via treatment with a PTEN inhibitor (Figure 4). 
These results demonstrate that mTORC1 signaling selectively regulates specific Hippo pathway 
components and their intracellular localization in a cell-type specific manner: in HepG2 cells, it 
regulates nuclear localization of TEAD1, while in MCF7 cells, it determines its expression levels. 
2.3. mTOR Inhibition Affects the Expression Levels of the Hippo Target TAZ in HepG2 Cells But Not 
MCF7 Cells 
To further investigate the relationship between the Hippo and mTOR pathways, we next examined 
the effect of mTOR inhibition on the Hippo target TAZ. In both cell lines, TAZ and P-TAZ are 
localized in the nucleus at low cell density, but translocate to the cytosol in response to increased cell 
density (Figure 5, Figure S3, Figure S4). However, inhibition of mTOR signaling via rapamycin 
treatment yielded no change in localization or expression of TAZ or P-TAZ in MCF7 cells (Figure S3). 
In contrast, we found that inhibition of the mTOR pathway via rapamycin treatment in HepG2 cells 
resulted in decreased expression levels of TAZ without affecting levels of P-TAZ (Figure 5 and   Cells 2012, 1  890 
 
 
Figure S4). Additionally, TAZ in rapamycin-treated HepG2 cells at low cell density appears to 
translocate to the cytosol (Figure 5), while TAZ in rapamycin-treated cells at high density appears to 
translocate to the nucleus, compared to controls (Figure 5). Interestingly, while inhibition of Akt 
decreases TAZ levels and causes an increase in its nuclear localization as is the case with rapamycin 
(mTORC1 inhibition with partial mTORC2 inhibition), to our surprise OSI-027 (mTORC1 + 
mTORC2 inhibition) treatment decreases TAZ levels but does not increase nuclear localization (Figure 
6A). A similar decrease in TAZ levels occurs upon reduction of serum levels (Figure 6B). These 
results indicate that mTORC1 signaling regulates levels of TAZ, while its localization to the nucleus 
may be more dependent on mTORC2 in high cell density conditions.  
Figure 2. Rapamycin treatment does not affect TEAD1 protein expression levels but 
affects its nuclear localization in HepG2 cells. TEAD1 (green) expression does not change 
with and without rapamycin treatment at low and high cell density conditions. Bottom 
panels represent the boxes in top images: localization of TEAD1 at low and high cell 
density conditions demonstrates that, in contrast to MCF7 cells, it is mainly nuclear in low 
density conditions, while it is less nuclear at high density conditions. Rapamycin treatment 
increases nuclear localization at high density conditions. TOPRO3 (blue) labels nuclei. Scale 
bars, 20 µm. 
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Figure 3. mTOR pathway inhibition increases TEAD1 levels in MCF7 cells. Elevated 
levels of TEAD1 (green) were observed at both high and low cell densities after treatment 
with rapamycin. Bottom panels represent the boxes in top images: localization of TEAD1 
at low and high cell density conditions demonstrates cytoplasmic localization that does not 
change with rapamycin treatment. TOPRO3 (blue) labels nuclei. Scale bars, 20µm. 
 
2.4. Discussion 
Previous studies have shown that the SWH signaling pathway is critical in regulating cellular 
development and homeostasis [2,7], and interference with pathway components results directly in 
dysregulation of tissue and organ size. Our results confirmed expression of the key SWH pathway 
machinery (Mob1, MST2, Lats2) transcripts in HepG2 and MCF7 cells. We also confirmed the 
transcriptional expression of several Ste20p-like kinases in HepG2 and MCF7 cells. Upon treatment 
with rapamycin, the transcript expression of both SWH pathway components and Ste20p-like kinases 
in these cell lines did not change, demonstrating that mTOR does not regulate these elements of the 
Hippo pathway at the transcriptional level. This data also suggests that select Ste20p-like kinases 
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Scrib) are not regulated by mTORC1 signaling. Despite the lack of effect on transcription levels, the 
known role of mTOR in promoting protein translation suggested the possibility that it may regulate 
components of the Hippo pathway at the translational level.  
Figure 4. Akt pathway inhibition increases TEAD1 levels in MCF7 cells. Elevated levels 
of TEAD1 (green) were observed at high cell density conditions after treatment with an 
Akt inhibitor. The observed effects of rapamycin were confirmed with the mTORC1/2 
inhibitor OSI-027. Panels on the right represent boxed images on the left: localization of 
TEAD1 at high cell density demonstrates cytoplasmic localization that does not change 
with drug treatment. TOPRO3 (blue) labels nuclei. Scale bars, 20µm. 
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Figure 5. mTOR pathway inhibition affects expression and localization of TAZ in HepG2 
cells. Decreased levels of TAZ (green) were observed at both high and low cell densities 
after treatment with rapamycin. Bottom panels represent the boxes in top images: 
localization of TAZ at low cell density conditions demonstrates mostly nuclear expression 
that becomes cytoplasmic upon rapamycin treatment, while in high density conditions, 
TAZ is mostly cytoplasmic in control cells but shifts to the nucleus upon rapamycin 
treatment. TOPRO3 (blue) labels nuclei. Scale bars, 20 µm. 
 
TEA Domain family member 1 (TEAD1) is a known homologue of the Drosophila melanogaster 
transcription factor Scalloped, a known effector of the Hippo pathway that interacts with WW-domain 
coactivators. In vertebrates, these coactivators are encoded by the YAP and TAZ genes and they 
promote cell cycle progression [18], cell proliferation, and differentiation [19]. TEAD1 has been 
shown to play a role in retaining TAZ in the nucleus to promote cell proliferation [20], mediate   
YAP-dependent growth control [21], and its knockdown has been shown to decrease cell   
proliferation [22]. While increases in TEAD1 expression levels are associated with decreased survival 
in prostate cancer [22], and in conjunction with TAZ induces epithelial-mesenchymal transition [3], 
there is limited data on the role of TEAD1 in cancer. Our immunocytochemical results demonstrate a 
differential effect of rapamycin on increasing TEAD1 levels in MCF7 but not HepG2 cells, and this 
was confirmed with the mTORC1/2 inhibitor OSI-027. This difference is likely due to a cell-type 
specific effect of TEAD1 in breast cancer cells that awaits further study.  Cells 2012, 1  894 
 
 
Figure 6. Akt pathway inhibition and changes in serum levels affects expression and 
localization of TAZ in HepG2 cells. (A) Decreased levels of TAZ (green) were observed at 
high cell density conditions after treatment with an Akt inhibitor but not with the PTEN 
inhibitor bpV(phen). (B) Decreased levels of TAZ were also observed at high cell density 
conditions after a reduction in serum levels. Panels on the right represent boxed images on 
the left: localization of TAZ in high cell density conditions demonstrates mostly 
cytoplasmic expression that does not change upon OSI-027 treatment but shifts to the 
nucleus upon Akt1/2 inhibitor treatment. TOPRO3 (blue) labels nuclei. Scale bars, 20 µm. 
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The lack of changes in P-YAP in response to rapamycin treatment suggests that there is no   
YAP-mediated interaction between the SWH and mTOR pathways both at the transcriptional and  
post-translational levels. However, our study was limited to the use of an antibody that recognizes 
phosphorylation at the Serine 127 and Serine 89 residues [23]. This accounts for the higher levels of  
P-YAP compared to total YAP seen in HepG2 cells. Therefore, it remains to be determined if 
additional phosphorylation sites may potentially mediate cross-talk between the two pathways.  
TAZ is a demonstrated transcriptional coactivator regulated by the Hippo pathway that promotes 
cell proliferation and epithelial-mesenchymal transition [23,24]. Phosphorylation at key residues by 
Hippo pathway kinases causes retention of TAZ in the cytoplasm and prevents its growth-promoting 
activity [22]. We did not observe changes in P-TAZ levels or intracellular localization upon rapamycin 
treatment in both cell lines. TAZ can be phosphorylated at four different serine residues (Ser89, Ser66, 
Ser117, Ser311) [22]. We examined only the Ser89 residue because it is most commonly dependent on 
Hippo signaling. It is possible that the expression levels of TAZ that has been phosphorylated at other 
sites in the protein change in response to rapamycin treatment. More importantly, our results 
demonstrate that the intracellular localization of TAZ is actively regulated in both MCF7 and HepG2 
cell lines. In conditions of high cell density, TAZ translocates to the cytosol and this is associated with 
contact-inhibition of cell growth. However, inhibition of mTOR signaling via rapamycin had no effect 
in MCF7 cells but decreased TAZ levels in HepG2 cells, as do decreases in serum levels. This 
decrease in expression was accompanied by TAZ translocation to the nucleus at high density, likely 
the result of inhibition of translation of proteins required for its cytosolic retention. Similarly, Akt 
inhibition decreases its expression levels and promotes its nuclear localization, consistent with the 
changes observed with rapamycin. Interestingly, while mTORC1 inhibition with rapamycin in high 
cell density conditions promotes the nuclear localization of TAZ, the mTORC1/2 inhibitor OSI-027 
has no effect on localization in HepG2 cells. This suggests a potential role for mTORC2 in the nuclear 
localization of TAZ upon mTOR inhibition.  
Based on our findings, TAZ represents a novel biomarker for investigation in liver cancer, and its 
responsiveness to rapamycin specifically in this type of tumor suggests a potential therapeutic 
intervention for hepatic tumors in which TAZ is upregulated. Elevated levels of TAZ have been 
correlated with breast cancer cell migration, invasion, and tumorigenesis, while TAZ knockdown in 
breast cancer cell lines have impaired the tumorigenic ability of those cells [25]. These findings have 
defined TAZ as an important regulator of breast cancer development and progression. However, the 
correlation of TAZ levels with other types of tumors has been limited to a few cases, including  
non-small cell lung cancer cell lines [26] and papillary thyroid carcinoma [27]. The decrease in TAZ 
levels upon rapamycin treatment suggests a potential role for the mTOR pathway in maintaining TAZ 
levels, and further studies of this mechanism in other cancers may help elucidate the role of Hippo 
signaling in tumorigenesis.  
3. Experimental Section  
3.1. Cell Lines and Cell Culture 
+HS*DQG0&)FHOOV$7&&0DQDVVDVZHUHFXOWXUHGLQ'XOEHFFR¶V0RGLILFDWLRQRI(DJOH¶V
Medium (4.5 g/L glucose, with L-glutamine and sodium pyruvate; Cellgro, Manassas) and   Cells 2012, 1  896 
 
 
supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies, Grand Island) and  
Penicillin-Streptomycin-Neomycin antibiotic mixture (Life Technologies, Grand Island) and grown at  
37 °C and 5% CO2. For experiments, cells were plated on 60 mm petri dishes and grown for 48 hours 
to 70%±80% confluence before drug treatment. Petri dishes were separated into triplicates, with each 
dish exposed to one of three conditions: (1) No drug treatment (control) (2) 0.1% DMSO (Fisher 
Scientific, Fair Lawn) or (3) n0 rapamycin in 0.1% DMSO (LC Laboratories, Woburn) and 
incubated for 24 hours. Rapamycin effectiveness was determined by effects on P-4EBP1 
immunofluorescence (Figure S5). Other drugs used in our study include: 10 nM Akt1/2 kinase 
inhibitor (Sigma-Aldrich, St. Louis), 100 nM bpV(phen) (Calbiochem, Billerica), and 500 pM   
OSI-027 (ChemieTek, Indianapolis). 
3.2. RNA Extraction, Purification and cDNA Synthesis 
Triplicate dishes of drug-treated cells were lysed using TRIzol® Reagent and processed as per 
manufacturer's protocol. RNA was then treated with DNase I (Roche, Indianapolis) for 30 minutes. 
RNA was extracted with Phenol/Chloroform/Isoamyl Alcohol (Fisher Scientific, Fair Lawn), 3M 
Sodium Acetate Trihydrate (Sigma, St. Louis), 1 mM EDTA, glycogen (Ambion, Austin) and ethanol. 
cDNA was synthesized using the Superscript® III First-Strand Synthesis System for RT-PCR (Life 
Technologies, Carlsbad).  For each condition, 1 µg of DNAse-treated RNA was used.  
3.3. Semi-Quantitative PCR Amplification of Target Genes 
PCR primers (Figure S6) were designed to span introns to ensure specificity of amplification. A 
100ng sample of cDNA was subjected to PCR using the following procedures: 94 °C for 3 minutes, 
followed  by  
34 cycles of 94 °C for 45 seconds, 55 °C for 30 seconds, and 72 °C for 90 seconds.  Samples were then 
incubated at 72° for 10 minutes. All cDNA synthesis and PCR procedures were performed using the 
Bio-5DG & 7KHUPDO &\FOHU PCR products were resolved in a 1% agarose gel. Each 
experimental condition and gene expression level was replicated in a minimum of four samples.  
3.4. Immunocytochemistry 
Primary antibodies used in our study included: TEAD1 (1:100; Lifespan Biosciences, Seattle), 
TAZ, P-TAZ (1:200; Ser89, Santa Cruz Biotechnology, Santa Cruz), P-4EBP1 (1:400), YAP, and  
P-YAP (1:100; Ser127, Cell Signaling Technology, Danvers). Cells were plated on poly-D-Lysine 
coated coverslips (BD Biosciences, Bedford) and grown to 80% confluence, washed once with PBS 
(Cellgro, Manassas), and fixed with 4% paraformaldehyde. Cells were washed three times with PBS, 
permeabilized with 0.05% Triton X-100/PBS and blocked with 10% NGS/PBS. Cells were then 
incubated overnight at 4 °C with primary antibody, rinsed twice with 10% NGS in 0.05% Triton  
X-100/PBS and incubated for two hours with secondary antibody coupled to FITC (Jackson 
ImmunoResearch Laboratories, West Grove) in a 1:400 dilution. Finally, coverslips were washed twice 
with PBS, incubated in TOPRO3 (Life Technologies, Eugene) with a 1:500 dilution and washed once 
with water. Coverslips were then mounted onto microscope slides using Vectashield (Vector Cells 2012, 1  897 
 
 
Laboratories, Burlingame) mounting medium and examined using a Carl Zeiss LSM 310 Laser 
Scanning Confocal Microscope. Each of the experimental findings was replicated with a minimum of 
five samples.  
4. Conclusions  
In this study we demonstrate expression of all components of the Hippo signaling pathway in both 
the HepG2 liver and MCF7 breast cancer cell lines, except YAP in MCF7 cells. mTOR inhibition via 
rapamycin treatment decreases TAZ levels in HepG2 but not MCF7 cells and increases TEAD1 levels 
in MCF7 but not HepG2 cells, while altering the nuclear localization of TAZ depending on the 
conditions of cell density (Figure 7). Akt inhibition causes similar effects to mTOR, increasing 
TEAD1 in MCF7 cells and decreasing TAZ levels in HepG2 cells, but causing nuclear accumulation 
of TAZ. Our findings suggest a novel selective role of the mTOR pathway in regulating these Hippo 
targets in a cell type-specific manner and highlight the potential role for mTOR inhibitors in regulating 
Hippo-signaling dependent tumors. 
Figure 7. Effects of rapamycin treatment on Hippo pathway components in HepG2 and 
MCF7 cells. Cytoplasmic (C) or nuclear (N) localization and downregulation (D) or   
upregulation (U) of Hippo pathway components at low density (left) and high density 
(right) conditions.  
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Supplementary Materials 
Figure S1. YAP is not expressed in MCF7 cells. (A-B) Immunofluorescent staining of 
YAP(A, green) and P-YAP (B, green) in MCF7 cells with and without rapamycin 
treatment at low and high cell density conditions. TOPRO3 (blue) labels nuclei. Scale bars, 
100µm. 
 Cells 2012, 1  901 
 
 
Figure S2. Rapamycin treatment does not affect YAP/P-YAP expression or localization in 
HepG2 cells. (A-B) Immunofluorescent staining of YAP (A, green) and P-YAP (B, green) 
in MCF7 cells with and without rapamycin treatment at low and high  cell density 
conditions demonstrates no changes. Bottom panels represent box in top images: 
localization of YAP or P-YAP at low and high cell density conditions demonstrates 
cytoplasmic localization and does not change with rapamycin treatment. TOPRO3 (blue) 
labels nuclei. Scale bars, 50 µm. 
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Figure S3. mTOR pathway inhibition does not affect TAZ/P-TAZ expression or 
localization in MCF7 cells. (A-B) Immunofluorescent staining of TAZ (A, green) and  
P-TAZ (B, green) in MCF7 cells with and without rapamycin treatment at low and high 
cell density conditions demonstrates no changes. Bottom panels represent box in top 
images: localization of TAZ and P-TAZ at low cell density conditions demonstrates   
mostly nuclear localization that does not change upon rapamycin treatment, while in high 
density conditions, TAZ and P-TAZ is cytoplasmic and does not change upon rapamycin 
treatment. TOPRO3 (blue) labels nuclei.  Scale bars, 20 µm.  
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Figure S4. Rapamycin treatment does not affect P-TAZ expression or localization in 
HepG2 cells. Immunofluorescent staining of P-TAZ (green) in HepG2 cells with and 
without rapamycin treatment at low and high  cell density conditions demonstrates no 
changes. Bottom panels represent box in top images: localization of P-TAZ at low cell 
density conditions demonstrates  mostly nuclear localization that does not change upon 
rapamycin treatment, while in high density conditions, P-TAZ is cytoplasmic and does not 
change upon rapamycin treatment. TOPRO3 (blue) labels nuclei. Scale bars, 20 µm. 
 
Figure S5. Rapamycin treatment decreases P-4EBP1 levels. Immunocytochemistry for the 
mTORC1 target P-4EBP1 (green) demonstrates a decrease in levels upon treatment with 
rapamycin. TOPRO3 (blue) labels nuclei. Scale bars, 20 µm. 
 Cells 2012, 1  904 
 
 
Figure S6. Nucleotide sequences of PCR primers used in the study. 
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